PartnershipMay 26, 2026, 07:02 AM
Olema Pharma Partners Bayer for OP-3136 Prostate Cancer Trial
AI Summary
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer AG to evaluate OP-3136, Olema's investigational KAT6 inhibitor, in combination with Bayer's NUBEQA (darolutamide). The Phase 1b/2 study will assess the safety, tolerability, and preliminary anti-tumor activity in approximately 36 patients with metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in H2 2026. Under the agreement, Bayer will supply darolutamide, Olema will lead the study, and both companies will jointly own clinical data and inventions, while Olema retains full global commercial rights to OP-3136.
Key Highlights
- Olema Pharma partnered with Bayer AG for a clinical trial collaboration.
- To evaluate OP-3136 (Olema's KAT6 inhibitor) with darolutamide (Bayer's NUBEQA ).
- Phase 1b/2 study targets metastatic castration-resistant prostate cancer (mCRPC).
- Study will enroll approximately 36 patients and initiate in H2 2026.
- Bayer will supply darolutamide; Olema will lead the study.
- Clinical data and inventions related to combined use will be jointly owned.
- Olema retains full global commercial and marketing rights to OP-3136.
Price Impact
More from OLMA